Background: The aim of the study was to evaluate the response to and toxicity of pre-operative radiochemotherapy containing raltitrexed (Tomudex) for resectable rectal adenocarcinoma. Patients and Methods: From November 2000 to June 2002, 18 consecutive patients staged T3 N0/N+ were treated with pre-operative chemotherapy (3 mg/m 2 of raltitrexed on days 1, 19, 38) and concurrent radiotherapy (RT) (50.4 Gy) in 6 weeks, followed by radical surgery within 8 weeks. Results: The treatment compliance was high. No major acute toxicity was reported. Concerning late toxicity, genitourinary adverse effects were prevalent. A complete response was observed in one patient (6%), partial response in eight (47%), stable disease in seven (41%) and progression in one case. Three-year actuarial disease-free and overall survival rates were 37% and 87.5%, respectively. Conclusion: Raltitrexed did not increase the pathological response rate compared with the rates obtained with use of preoperative RT alone and reported in the literature. Acute morbidity was low and acceptable, while late toxicity was considerable, prevalently concerning sexual dysfunction and urinary complications.

Pre-operative radiochemotherapy with raltitrexed for resectable locally-advanced rectal cancer : a phase II study / M.C. Leonardi, M.G. Zampino, F. Luca, B.A. Jereczek-Fossa, E. Petazzi, B. Tatani, R. Lazzari, R. Biffi, K. Lorizzo, E. Magni, D. Scanniffio, F. Orsi, G. Bonomo, G. Petralia, C. Trovato, C. Crosta, B. Andreoni, R. Orecchia. - In: ANTICANCER RESEARCH. - ISSN 0250-7005. - 26:3B(2006 May), pp. 2419-2423.

Pre-operative radiochemotherapy with raltitrexed for resectable locally-advanced rectal cancer : a phase II study

B.A. Jereczek-Fossa;G. Petralia;B. Andreoni
Penultimo
;
R. Orecchia
Ultimo
2006

Abstract

Background: The aim of the study was to evaluate the response to and toxicity of pre-operative radiochemotherapy containing raltitrexed (Tomudex) for resectable rectal adenocarcinoma. Patients and Methods: From November 2000 to June 2002, 18 consecutive patients staged T3 N0/N+ were treated with pre-operative chemotherapy (3 mg/m 2 of raltitrexed on days 1, 19, 38) and concurrent radiotherapy (RT) (50.4 Gy) in 6 weeks, followed by radical surgery within 8 weeks. Results: The treatment compliance was high. No major acute toxicity was reported. Concerning late toxicity, genitourinary adverse effects were prevalent. A complete response was observed in one patient (6%), partial response in eight (47%), stable disease in seven (41%) and progression in one case. Three-year actuarial disease-free and overall survival rates were 37% and 87.5%, respectively. Conclusion: Raltitrexed did not increase the pathological response rate compared with the rates obtained with use of preoperative RT alone and reported in the literature. Acute morbidity was low and acceptable, while late toxicity was considerable, prevalently concerning sexual dysfunction and urinary complications.
Neoadjuvant chemoradiotherapy; Raltitrexed; Rectal carcinoma
Settore MED/18 - Chirurgia Generale
Settore MED/36 - Diagnostica per Immagini e Radioterapia
mag-2006
Article (author)
File in questo prodotto:
File Dimensione Formato  
2419.full.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 92.83 kB
Formato Adobe PDF
92.83 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/30024
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact